Main Menu

Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.

Engineered Influenza Neuraminidase Antigens represent a cutting-edge approach to revolutionize Influenza vaccine development. This technology harnesses the sequences of neuraminidase (NA) proteins, pivotal components of the Influenza virus, to create stabilized tetramers for multiple NA subtypes. By identifying specific mutations, the technology enables the control of NA protein conformations, particularly closed states, which significantly enhances their stability.

The technology at hand represents a pivotal advancement in the early detection of Type 1 Diabetes (T1D) and the associated autoimmune processes. By utilizing electrochemiluminescence (ECL)-based assays, it enables the precise measurement of diabetes-associated antibodies, particularly Insulin Autoantibodies (IAA) in non-obese diabetic (NOD) mice and anti-insulin antibodies (IA) in individuals with Type 1 diabetes. Notably, these assays are non-radioactive, ensuring safety and compliance, while also offering exceptional reproducibility and efficiency.

The technology involves the use of specialized cell lines, including HEK 293 cells expressing human CCR1 and CCR2, along with plasmids encoding mouse CCR1 (Ccr1) and CCR2B (Ccr2), as well as their corresponding human receptor sequences. These tools serve as crucial components in the study of chemokine receptors' functions, particularly in the context of inflammatory diseases. By manipulating and analyzing these receptors, researchers can gain insights into their roles in cellular responses related to inflammation.

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.

The technology in focus involves monoclonal antibody CI.11B11.B4.C4, a pioneering biological tool designed to target and bind with high specificity to both isoforms of mouse APOBEC3, mA3 and mA3d5. APOBEC3 proteins play a crucial role in innate immune defense against retroviruses by inducing hypermutation in the viral genome, thereby hindering viral replication and infection.

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments.

The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain's C-terminus within the ribosome's A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized.

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.